WallStreetZenWallStreetZen
Analyst Ranking
Bottom 19%
#3683 out of 4529 analysts
Average Return
-0.68%
Win Rate
45%9 out of 20
Risk vs Reward
Poor
Good

Matthew Kaplan's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Ardelyx IncARDX
+82.50%$4.00$7.30
2023-08-02 -
2024-03-28
Strong Buy
Reata Pharmaceuticals IncRETA
+64.10%$100.90$165.58
2023-06-28 -
2023-07-31
Strong Buy
Liquidia CorpLQDA
+56.73%$5.20$8.15
2022-07-21 -
2023-07-21
Strong Buy
Albireo Pharma IncALBO
+52.86%$22.59$34.53
2017-02-15 -
2018-02-16
Strong Buy
United Therapeutics CorpUTHR
+48.67%$168.00$249.76
2022-02-24 -
2023-02-24
Strong Buy

Matthew Kaplan Analyst Color

Get additional color on Matthew Kaplan's coverage of popular stocks

Matthew Kaplan's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Liquidia CorpLQDA
2Strong Buy$30.00+103.39%Maintains
3 months ago
Ardelyx IncARDX
3Strong Buy$8.50+16.44%Maintains
8 months ago
United Therapeutics CorpUTHR
3Strong Buy$268.00+16.66%Maintains
8 months ago
Reata Pharmaceuticals IncRETA
3Hold$172.50+0.08%Downgrades
8 months ago
Avadel Pharmaceuticals PLCAVDL
1Strong Buy$16.00-5.27%Maintains
a year ago
Tg Therapeutics IncTGTX
1Strong Buy$37.50+146.55%Maintains
a year ago
Kiora Pharmaceuticals IncKPRX
2Strong Buy$119.00N/AReiterates
a year ago
Beyond Air IncXAIR
1Strong Buy$23.00N/AMaintains
2 years ago
Antares Pharma IncATRS
1HoldN/AN/ADowngrades
2 years ago
Allena Pharmaceuticals IncALNAQ
1HoldN/AN/ADowngrades
2 years ago
Reneo Pharmaceuticals IncRPHM
1Strong Buy$45.00N/AInitiates Coverage On
2 years ago
Tempest Therapeutics IncTPST
1HoldN/AN/ADowngrades
3 years ago
Lipocine IncLPCN
1Strong Buy$51.00N/AUpgrades
3 years ago
Cogent Biosciences IncCOGT
1Strong Buy$16.00N/AInitiates Coverage On
3 years ago
Protara Therapeutics IncTARA
1Strong Buy$45.00N/AInitiates Coverage On
4 years ago
Athenex IncATNXQ
1Strong Buy$540.00N/AInitiates Coverage On
5 years ago
Albireo Pharma IncALBO
1Strong Buy$40.00N/AInitiates Coverage On
7 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.